84 citations
,
September 2008 in “Developmental biology” Retinoic acid-binding proteins in skin are regulated by β-catenin and Notch signalling.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
January 1993 in “Inpharma Weekly” A new food supplement was highly effective in curing hair loss in young men.
October 2022 in “The Journal of Clinical Pharmacology” Men with early-onset hair loss have less cardiometabolic benefit from bromocriptine.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
138 citations
,
November 1977 in “Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics” 5 citations
,
May 2023 in “Microbial Cell Factories” A stable, active version of a growth factor was made in bacteria, showing promise for medical use.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
January 2008 in “Journal of Medicinal Chemistry” Finasteride may cause sexual and psychological side effects by affecting an enzyme related to epinephrine.
May 2005 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Truncated LTBP-1 disrupts TGF-beta signaling, affecting hair growth.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
December 2024 in “Veterinary Dermatology” A sugar glider had a rare skin cancer that worsened despite treatment, highlighting the need for thorough checks in exotic pets.
13 citations
,
April 2020 in “European Journal of Dermatology” Apremilast showed mixed results for treating severe alopecia areata.
October 2020 in “Pediatrics in Review” The newborn was diagnosed with a rare skin disorder causing blisters, which requires careful wound care and family support.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
January 2025 in “Journal of Prescribing Practice” 2 citations
,
June 2013 in “Journal of Clinical Pathology” The LMNA mutation affects skin structure even in asymptomatic carriers.
August 2018 in “Journal of the American Academy of Dermatology” Biotin treatment for hair, nail, and skin disorders has weak evidence and should not be recommended unless new research shows clear benefits.
November 2005 in “The Journal of Urology” 49 citations
,
September 2004 in “Journal of the European Academy of Dermatology and Venereology” Careful light microscopy is crucial for detecting mild cases of pili annulati, which weakens hair and varies widely in expression.
December 2025 in “Actas Dermo-Sifiliográficas” Bicalutamide may improve hair growth in postmenopausal women with mild side effects.
1 citations
,
February 2022 in “Journal of the American Academy of Dermatology” Taking biotin supplements can be risky and often lacks evidence of effectiveness for skin, hair, and nail issues.
7 citations
,
March 2022 in “Molecules” 5-Bromo-3,4-dihydroxybenzaldehyde could potentially help hair growth by activating certain cell pathways and inhibiting others.
23 citations
,
January 1991 in “Journal of Animal Science” Biotin supplementation in sow diets is unnecessary.
26 citations
,
January 2005 in “PubMed” RUM-loaded SLN shows promise for treating acne and hair loss topically.
January 2011 in “Bloomsbury Academic eBooks” May 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Bhringaraja is a herb with many health benefits, including liver protection, hair growth, pain relief, and more.
2 citations
,
October 2023 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.